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 Abstract 
 We previously described flow cytometry-based methods for scoring the incidence of 
micronucleated reticulocytes (MN-RET) and PIG-A mutant phenotype reticulocytes (MUT RET) 
in rodent and human blood samples. The current report describes important methodological 
improvements for human blood analyses, including immunomagnetic enrichment of CD71-
positive reticulocytes prior to MN-RET scoring, and procedures for storing frozen blood for later 
PIG-A analysis. Technical replicate variability in MN-RET and MUT RET frequencies based on 
blood specimens from 14 subjects, intra-subject variability based on serial blood draws from 6 
subjects, and inter-subject variation based on up to 344 subjects age 0 to 73 years were 
quantified. Inter-subject variation explained most of the variability observed for both endpoints (≥ 
77%), with much lower intra-subject and technical replicate variability. The relatively large 
degree of inter-subject variation is apparent from mean and standard deviation values for MN-
RET (0.15 ± 0.10%) and MUT RET (4.7 ± 5.0 per million, after omission of two extreme 
outliers). The influences of age and sex on inter-subject variation were investigated, and neither 
factor affected MN-RET whereas both influenced MUT RET frequency. The lowest MUT RET 
values were observed for subjects < 11 years old, and males had moderately higher 
frequencies than females. These results indicate that MN-RET and MUT RET are automation-
compatible biomarkers of genotoxicity that bridge species of toxicological interest to include 
human populations. These data will be useful for appropriately designing future human studies 
that include these biomarkers of genotoxicity, and highlight the need for additional work aimed 
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1. Introduction 
 DNA damage plays integral roles in many human diseases, including cancer, the 
numerous Mendelian genetic diseases, atherosclerosis, and DNA-repair deficiency diseases 
[Hoeijmakers, 2009]. In addition to the role genomic damage plays in cancer and other 
diseases, a consortium of experts at the Health and Environmental Sciences Institute have 
recently advocated that mutation should be considered an adverse outcome in its own right 
[Heflich et al., 2020]. Despite its importance, the systematic study of DNA damage and 
identification of causative factors are hampered by the lack of rapid, sensitive, and economical 
in vivo assays that can be readily applied to human specimens. Adaptation of two flow 
cytometry-based assays that are widely used for rodent studies to human blood samples may 
overcome these obstacles—micronucleated reticulocyte (MN-RET) and PIG-A mutant 
reticulocyte (MUT RET) analyses [Dertinger et al., 2004, 2011]. 
 The MN-RET assay is responsive to chromosomal damage that results in DNA double-
strand breaks or mal-segregation of chromosomes [Heddle, 1973; MacGregor et al., 1980; 
Hayashi et al., 2000], and the PIG-A assay reports the occurrence of inactivating gene 
mutations [Araten et al., 1999; Gollapudi et al., 2015]. Together they represent complementary 
biomarkers that cover a wide range of genotoxic lesions. We anticipate that an efficient and 
reliable human blood-based strategy for quantifying chromosomal damage and gene mutation 
would benefit myriad lines of investigation. These include, but are not limited to: identification of 
genotoxic environmental or occupational exposures; development of pharmaceuticals, 
consumer products, and industrial chemicals with inherently lower genotoxicity; identification of 
unhealthy lifestyle choices; studying the consequences of diagnostic and therapeutic radiation; 
identifying subjects at high risk for certain diseases; and detection of genotypes associated with 
increased rates of DNA damage. 
 This laboratory and others have previously reported significant progress adapting these 
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Offer et al., 2005; Witt et al., 2007; Dobrovolsky et al., 2011; Horibata et al., 2016; Cao et al., 
2016, 2020a,b; Khattab et al., 2017; Haboubi et al, 2019]. Here, we report methodological 
improvements that overcome barriers to wide-spread use. One obstacle stems from the fact that 
the flow cytometic approach to scoring peripheral blood micronuclei is based on the analysis of 
the most immature fraction of erythrocytes, i.e., the CD71-positive fraction of reticulocytes, 
which are present at a very low frequency of about 0.1% in the human blood circulation. 
Focusing analyses on these most immature reticulocytes is advantageous because it minimizes 
the impact of splenic filtration function has on micronucleated erythrocyte frequencies [Dertinger 
et al., 2004, 2007]. However, this low frequency has made it challenging to interrogate adequate 
numbers of reticulocytes to precisely measure %MN-RET. Informed by work by Grawé and 
colleagues [2005], we have developed an immunomagnetic method that overcomes this 
problem by enriching CD71-positive reticulocytes prior to flow cytometric analysis. 
 Another limitation has been the requirement to label and analyze blood samples for the 
PIG-A assay within several days of collection. Here, we report that methods recently developed 
for freezing and later thawing rodent blood samples for mutation analysis [Avlasevich et al., 
2019] are effective with human blood. This is an important advance that overcomes numerous 
logistical issues that would otherwise interfere with many, if not most, human biomonitoring 
studies. 
 Another significant barrier to routinely incorporating MN-RET and MUT RET biomarkers 
into human population studies has been the scarcity of data from presumably healthy human 
subjects. In order to design adequately powered studies, it is important to understand the 
distribution of healthy volunteer data once technical sources of variability have been minimized, 
and to be cognizant of host factors that have an appreciable influence on MN-RET and MUT 
RET frequencies. Therefore, after optimizing these assays, we assessed technical replicate 
variability and intra-subject variability over a 5-week period based on ≥ 6 individuals, and inter-
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on MN-RET and MUT RET frequencies. The results of these experiments form the basis of the 
recommendations we provide for effectively incorporating these biomarkers into human 
biomonitoring studies. 
 
2. Materials and Methods 
2.1 Mouse Study 
2.1.1 Mice 
Male CD-1 mice were purchased from Jackson Laboratories (Bar Harbor, Maine). Mice 
were allowed to acclimate for at least one week prior to treatment, and were handled in 
accordance with the standards established by the U.S. Animal Welfare Acts set forth in the 
National Institutes of Health (NIH) guidelines. All procedures were reviewed and approved by 
the University of Rochester‘s Committee on Animal Resources. Purina Mills Rodent Chow 5001 
and water were available ad libitum. 
 
2.1.2 Mouse Blood Micronucleus Assay: Reagents 
 Absolute methanol and heat-inactivated fetal bovine serum (FBS; cat. no. 89510-186) 
were from VWR, Radnor, PA. Reagents used for flow cytometric MN-RET scoring 
(Anticoagulant Solution, Buffer Solution, DNA Stain, Anti-CD71-FITC and Anti-CD61-PE 
Antibodies, RNase Solution, and Malaria Biostandards) were from In Vivo MicroFlow® PLUS-M 
Kits, Litron Laboratories, Rochester, NY. FITC Selection Cocktail and Magnetic Nanoparticles 
(cat. no. 18555) were from STEMCELL Technologies Inc., Vancouver, Canada.  
 
2.1.3 Treatment, Blood Collection 
 At the time of treatment mice were approximately 6 weeks old. Ionizing radiation doses 
were 0.5, 1, 2, and 4 Gy, and sham irradiation was used as the negative control. Three mice 
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exposure to 137Cs gamma rays. The dose rate was approximately 2 Gy per minute. After 
irradiation, the mice were maintained in groups of 3 per cage in a pathogen-free room. Blood 
samples were collected 24 hr post-exposure via an incision to a tail vein after mice were 
warmed briefly under a heat lamp. Approximately 50 μL of free-flowing blood was collected into 
tubes containing 200 μL kit-supplied Anticoagulant Solution which was maintained at room 
temperature until fixation occurred (within 4 hr). Blood samples were fixed with ultracold 
methanol according to Mouse MicroFlowPLUS Kit instructions. These fixed blood specimens were 
returned to the ultracold freezer for storage until flow cytometric analyses were performed as 
described below. 
 
2.1.4 Mouse Blood Micronucleus Assay: Sample Processing and Flow Cytometric Analysis 
 Fixed blood samples were washed out of methanol, cells were pelleted via 
centrifugation, and supernatants were aspirated according to manufacturer recommendations 
(In Vivo MicroFlow® PLUS-M Kit instruction manual, www.litronlabs.com). Tubes were gently 
tapped to resuspend the cells and 100 µL of Buffer Solution were added. The entire volume of 
each tube was transferred into a new 96-well round bottom assay plate (Falcon cat. no. 353910) 
with pre-aliquoted 100 µL working Labeling Solution (anti-CD71-FITC, anti-CD61-PE and 
RNase). Samples were incubated for 30 min at 4C and then 30 min at room temperature, at 
which point cells were resuspended by gentle pipetting and transferred directly into 1.5 mL ice-
cold Buffer + 1% FBS that was pre-aliquoted into wells of a 96-well deep-well plate (Axygen 
Scientific cat. no. P-DW-20-C). Cells were collected via centrifugation at 340 x g for 5 min. After 
centrifugation and aspiration of supernatant, cells were resuspended in 75 µL ice-cold Buffer 
Solution and kept cold and protected from light. A small aliquot (10 µL) of each cell suspension 
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used for standard MicroFlow sample analysis and stored at 4C until flow cytometric analysis 
occurred as described below (same day).  
 The remainder (majority) of each sample was used for reticulocyte enrichment. The 
entire volume of labeled cells was moved to a new well of a 96-well round bottom assay plate 
(Falcon cat. no. 353910) containing 50 µL of FITC selection cocktail (5 µL per 100 µL of Buffer), 
mixed gently by pipetting, and incubated at room temperature for 15 min. Cells were then 
moved to a new set of wells containing 50 µL of magnetic nanoparticles, mixed well and 
incubated for 10 min at room temperature. Cell suspensions (150 µL) were transferred to a new 
set of wells on a standard 96-well round bottom plate and a 96-well format Magnetic Bead 
Extractor (V&P Scientific‘s Magnetic Bead Separation Extractor, cat. no. 407AM-N) that was 
sheathed with a PCR cover plate (V&P Scientific‘s PCR plate, cat. no. VP 407AM-N-PCR). The 
magnetic beads with attached CD71-FITC cells were extracted from the cell mixture after 10 
min incubation at room temperature. The magnet and cover were then moved into wells of a 
sister plate containing 150 µL per well pre-aliquoted DNA Staining Solution. At this point, the 
cover plate was detached from the magnetic pins and the beads were released into the DNA 
Staining Solution. The plate was stored at 4C and protected from light until flow cytometric 
analysis occurred as described below (same day). 
 Samples were analyzed by a flow cytometer equipped with a 488-nm laser 
(FACSCanto™ II running FACSDiva™ v6.1.3, Becton Dickinson, San Jose, CA). Anti-CD71-
FITC, anti-CD61-PE, and propidium iodide fluorescence signals were detected in the FITC, PE, 
and PerCP-Cy5.5 channels, respectively. The gating logic used to ensure that quantitative 
analyses of erythrocyte subpopulations where not contaminated by other cellular or noncellular 
events has been described previously [Dertinger et al., 2004]. Calibration of the flow cytometer 
was accomplished by staining malaria-infected erythrocytes in parallel with test samples on 
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RETs per blood sample were evaluated for micronuclei, and the percentage of MN-RET and 
RET were calculated with Microsoft® Excel for Mac (v16.16.14).  
 
2.1.5 Statistical Analyses 
 Each mouse blood sample was split between two methods to generate %MN-RET 
values—standard MicroFlow analysis, and MicroFlow analysis following immunomagnetic 
enrichment of CD71+ RET. A linear fit was calculated in Excel. The resulting slope factor (m) 
was used to characterize accuracy, while the correlation coefficient (r2) was calculated to 
describe precision. As described in the fundamental works of Altman and Bland [1983], a 
correlation analysis does not describe measurement performance sufficiently. Therefore, the 
methodology proposed by Bland and Altman was also applied, also using Excel. In doing so, 
differences versus averages of %MN-RET values with and without immunomagnetic separation 
were plotted to describe bias and dispersion structures. Upper and lower limits of agreement 
were calculated to provide additional quantitative information about method performance. 
 
2.2 Human Subject Studies 
2.2.1 Subject Information 
 363 subjects, all under IRB-approved protocols, provided informed consent and donated 
blood sample(s) via venipuncture of the median cubital or cephalic vein at the cubital fossa. 
Blood was collected into a single 4 or 10 mL K2-EDTA vacutainer tube. The sources of the blood 
samples and subject characteristics are described in Table I. Thirty-seven volunteers provided 
blood samples at the University of Rochester Medical Center or an affiliated clinic, in which case 
the local samples were transported to Litron in Exakt Paks with -20°C ice packs to keep them 
cold but not frozen during same day delivery. The majority of the samples (300) were purchased 
from Biological Specialty Company (Colmar, PA). These samples, as well blood collected at 
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were shipped in Exakt Pak or comparable containers with -20°C ice packs in order to keep them 
cold, not frozen during FedEx First Overnight delivery service.  
 
2.2.2 Human Blood Micronucleus Assay: Reagents 
 Absolute methanol and heat-inactivated fetal bovine serum (FBS; cat. no. 89510-186) 
were from VWR, Radnor, PA. Reagents used for flow cytometric MN-RET scoring 
(Anticoagulant Solution, Buffer Solution, DNA Stain, Anti-CD71-FITC and Anti-CD61-PE 
Antibodies, RNase Solution, and Malaria Biostandards) were from Prototype In Vivo 
MicroFlow® PLUS-H Kits, Litron Laboratories, Rochester, NY. Anti-FITC MicroBeads, MS 
Columns, and an OctoMACSTM Separator were from Miltenyi Biotec, Bergisch Gladbach, 
Germany.  
 
2.2.3 Human Blood Micronucleus Assay: Sample Processing and Flow Cytometric Analysis  
 The methods for preparing human blood samples for MN-RET scoring are similar to 
those described previously [Dertinger et al., 2004, 2007]. However, after incubating fixed blood 
samples with RNase, anti-CD71-FITC, and anti-CD61-PE, the cells were exposed to an anti-
FITC microbead solution. That is, superparamagnetic anti-FITC MicroBeads in Buffer Solution + 
1% FBS (5 µL /100mL) were added to each sample in a volume of 100 µL and were mixed with 
gentle pipetting. Following a 30 min incubation at 4C, 1 mL cold Buffer Solution + 1% FBS was 
added to each sample and cells were mixed with gently pipetting. Each sample was divided into 
two fractions: ―pre-column‖ and ―post-column‖. For pre-column samples, a 20 µL aliquot of each 
cell suspension was added to 280 µL working DNA Stain and samples were placed on ice or at 
4C until flow cytometric analysis occurred as described below (same day). The remainder 
(majority) of each sample was applied to a pre-wetted Miltenyi MS Column suspended in an 
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column was washed three times with 500 µL Hank‘s Balanced Salt Solution + 1% FBS. At this 
point each MS column was removed from the magnetic field and placed onto a 15 mL centrifuge 
tube. Two mL Hank‘s Balanced Salt Solution + 1% FBS was added to each column reservoir to 
gently flush out the bound reticulocytes using the plunger supplied with the columns. After 
centrifugation (5 min at 800 x g) and aspiration, cell pellets were tapped loose, and stored on 
wet ice until flow cytometric analysis occurred as described below (same day).  
 At the beginning of each FCM analysis day, instrumentation and acquisition/analysis 
software parameters were calibrated based on the fluorescence of a biological standard— kit 
supplied malaria-infected rat blood (methanol fixed). As described previously, this sample 
guided photomultiplier tube voltages and compensation settings to resolve parasitized 
reticulocytes and also guided the position of the micronucleus scoring region. Data acquisition 
and analyses were performed using a FACSCalibur flow cytometer providing 488 nm excitation, 
running CellQuest™ Pro software v5.2.  
 Once photomultiplier tube voltages and compensation settings were configured with the 
malaria biostandard, the pre- and post-column paired samples were analyzed. Pre-column 
sample data acquisition occurred until 300,000 total erythrocytes were collected. While the pre-
column sample was being analyzed, 300 µL of the same working DNA stain was added to each 
post-column tube and the entire volume was transferred into a standard flow cytometer tube. 
Each sample was analyzed so that at least 10,000, but preferably 20,000 CD71-positive RET 
were analyzed. Note that we do not report %MN-RET for 18 of 356 samples (5% of total) 
because pre-column RET was < 0.02% and we were unable to acquire at least 10,000 RET. 
 
2.2.4 Human Blood PIG-A Assay: Reagents 
 Lympholyte®-H was purchased from CedarLane, Burlington, NC. Anti-PE MicroBeads, 
LS Columns, and QuadroMACSTM Separator were from Miltenyi Biotec, Bergisch Gladbach, 
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purchased from Invitrogen, Carlsbad, CA. Anticoagulant Solution, balanced salt solution (BSS), 
Nucleic Acid Dye Solution (a 1000-fold dilution of SYTO® 13 dye in DMSO), anti-human-CD59-
PE (clone OV9A2), anti-human-CD55-PE (clone 143–30), anti-human-CD45-PE (clone HI30), 
and anti-human-CD61-PE (clone VI-PL2) were from Prototype Human MutaFlow® Kits (Litron 
Laboratories, Rochester, NY). Blood Freezing and Blood Thawing Solutions A and B were from 
MutaFlow® Blood Freezing and Thawing Kits (Litron Laboratories, Rochester, NY). 
 
2.2.5 Human Blood PIG-A Assay, Sample Processing and Flow Cytometric Analysis   
 The method for preparing human blood samples for MUT RET scoring is similar to that 
described previously [Dertinger et al., 2015]. Two differences relative to the initial report are 
noteworthy. First, we scaled up reagents to label and analyze 200 µL blood (or 240 µL of 
frozen/thawed blood) per specimen as opposed to 100 µL. Second, since an effective blood 
freezing and thawing protocol was established (described below), a large portion of the PIG-A 
data reported herein were from samples that were frozen and later thawed for deferred flow 
cytometric analysis.  
 Freezing Solution (1 mL) was aliquoted into pre-labeled cryovials prior to freezing and 
maintained at room temperature. Upon receipt, human whole blood cells were gently 
resuspended by pipetting and 240 µL of blood was transferred into the Freezing Solution. 
Samples were incubated in Freezing Solution at room temperature for 5 min then transferred to 
a -75 to -85°C freezer. Samples were frozen for at least 48 hr before PIG-A analysis. 
 On the day of FCM analysis, up to 12 frozen blood samples were removed from the 
ultracold freezer and quickly thawed in a 37C water bath. Once thawed (about 2 min), blood 
suspensions were moved to new pre-labeled 50 mL centrifuge tube. 0.9 mL Thawing Solution A 
was added to each tube and mixed by gentle pipetting up and down 6-8 times. Blood samples 
were incubated at room temperature for 5 min. After incubation, 4.5 mL Thawing Solution B was 
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temperature. Thawing Solution B was added again at 5 min intervals, first 5.4 mL and then 28.8 
mL. After the final 5 min incubation, samples were centrifuged at 340 x g for 5 min, supernatants 
were aspirated, 100 µL BSS were added to each tube, and the cells were resuspended with 
gentle pipetting.  
 The entire volume of each thawed blood sample was layered onto 1.5 mL room 
temperature Lympholyte-H that was pre-aliquoted into wells of a deep-well 96-well plate 
(Axygen Scientific, 2 mL deep-well plate, cat. no. P-DW-20-C). In the case of never-frozen 
blood, 200 µL of blood was layered onto the Lympholyte-H. The plate was centrifuged at 800 x 
g for 20 minutes and supernatants were aspirated with a multi-channel aspirator with a fixed 
bridge (V&P Scientific, San Diego, CA). The platelet/leukocyte-depleted pellets were 
resuspended by gentle pipetting after 130 µL BSS were added to each well. The contents of 
each well were washed with an additional 1.5 mL cold BSS + 2%FBS that was pre-aliquoted 
into a new 96-well deep-well plate and the cells were collected via centrifugation for 10 min at 
235 x g. 100 µL BSS were added to each well and the erythrocyte-enriched pellets were mixed 
by gentle pipetting, and 190 µL of each were transferred to new wells of the deep-well plate 
containing 200 µL working antibody solution (300 µL anti-CD59-PE stock, 12.5 µL anti-CD55-
PE, 100 µL anti-CD61-PE, 50 µL anti-CD45-PE in 537.5 µL BSS + 2% FBS). After cells were 
incubated with antibodies for 30 min at 4°C, cells were resuspended with gentle pipetting using 
a multi-channel pipettor and then transferred to new wells of a deep-well plate with pre-aliquoted 
1.5 ml of BSS + 2% FBS. Following centrifugation for 5 min at 340 x g, the supernatants were 
aspirated using a multi-channel bridge aspirator and 200 µL superparamagnetic anti-PE 
MicroBeads in BSS + 2% FBS (300 µL per mL) were added to each well. Cells and beads were 
mixed and incubated at 4°C for 30 min, 1.5 mL BSS + 2% FBS were added to each well after 
incubation and cells were mixed by gentle pipetting. The plate was centrifuged at 340 x g for 5 
min, and supernatants were removed with a multi-channel fixed bridge aspirator, then 1 mL BSS 
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sample, 10 µL of each sample were added to 990 µL BSS with Nucleic Acid Dye Solution and 
CountBright Absolute Counting Beads (30 µL/mL). The pre-column samples were incubated at 
room temperature and protected from light for 30 min, after which time they were stored on ice 
until flow cytometric analysis occurred as described below. The remainder of each sample was 
applied to a pre-wetted Miltenyi LS Column suspended in a QuadroMACS Separator. Once the 
column reservoir was empty, 5 mL BSS + 2% FBS were added to ensure mutant phenotype 
cells were fully eluted (and collected into a 15 mL polypropylene tube). The eluates were 
centrifuged for 5 min at 800 x g, supernatants were aspirated, the pellets were tapped loose, 
and 300 µL of the same preparation of BSS with Nucleic Acid Dye Soluton and CountBright 
Beads used to prepare pre-column samples were added to each pellet. These post-column 
samples were incubated at room temperature and protected from light for 30 min. Samples were 
then placed on ice until flow cytometric analysis occurred as described previously on the same 
day [Dertinger et al., 2015]. 
 Samples were analyzed by a flow cytometer equipped with a 488-nm laser 
(FACSCalibur, BD, San Jose, CA). Nucleic Acid Dye, anti-CD59-PE, anti-CD55-PE, anti-CD45-
PE, anti-CD61-PE, and Counting Beads fluorescence signals were detected in the FITC, PE, 
and PerCP-Cy5.5 channels. Calibration of the flow cytometer was accomplished by generating 
an Instrument Calibration Standard on each day data acquisition occurred. The resulting 
samples provided sufficient numbers of mutant-mimic cells (RBCs that were stained with 
Nucleic Acid Dye but not incubated with antibody solution), and were used for optimizing 
photomultiplier tube voltages and fluorescence compensation settings. The position of the 
mutant mimics also provided a rational approach for defining the vertical demarcation line used 
to distinguish mutant phenotype cells from wild-type cells.  
 After PMT voltages and electronic compensation setting were defined with the 
Instrument Calibration Standard, pre- and post-column samples were moved into standard flow 
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min for every pre-column sample, and 3 min (i.e., until nearly the entire volume was depleted), 
for each post-column sample. 
  
2.2.6 Statistical Analyses  
 The formulas used to calculate MUT RET frequencies based on pre- and post-
immunomagnetic column data have been published [Dertinger et al., 2012] and are described in 
MutaFlow kit manuals (www.litronlabs.com). The incidence of MN-RET is expressed as 
frequency percent, while the incidence of MUT RET is expressed as number per 106 cells. For 
statistical evaluations, MN-RET and MUT RET frequencies were log(10) transformed.  
 JMP software‘s Variability Chart platform was used to study sources of variability in MN-
RET and MUT RET frequencies (JMP v12.0.1, SAS Institute Inc., Cary, NC). Specifically, the 
restricted maximum likelihood (REML) estimation of variance components was utilized, with the 
specification ―nested‖ model type. REML is a statistical method that is a modification of 
maximum likelihood estimation, which allows the generalization of the 'classic' regression and 
analysis of variance (ANOVA) statistical techniques to a wider series of experiments. For more 
information, the interested reader is directed to Corbeil and Searle, 1976. We utilized REML to 
evaluate the variability of MUT RET values attributable to subject, blood storage condition, and 
technical replicate. In other instances, REML was used to evaluate variability of MN-RET and 
MUT RET values attributable subject, blood collection time, and technical replicate.  
 Two-way ANOVA was used to investigate whether the factors age group, sex, and age 
group x sex interaction significantly affected MN-RET and MUT RET frequencies (JMP v12.0.1). 
Significance was evaluated at the 5% level. For these analyses, each subject was categorized 
into one of eight age groups: <1, 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, and 61+ years of age. 
When two-way ANOVA was significant, a Tukey-Kramer test was used to identify the source of 
the variation (alpha = 0.05). 
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against subject age. Linear and polynomial curves were fitted, and the reported p-values 
represent a test of the hypothesis that the true slope coefficients are zero. Said another way, the 
test evaluates whether a particular fitted model explains the data significantly better than a 
mean fit line. Note that, in the case of MUT RET, these analyses were broken out by sex, since 
two-way ANOVA had indicated these values were affected by sex. A similar fit Y by X analysis 
was performed to consider the relationship between individuals‘ MN-RET and MUT RET 
frequencies. 
 Regression analysis was performed for every subjects‘ MUT RET and corresponding 
mutant erythrocyte (mutant RBC) frequencies. Additionally, Bland-Altman analysis was 
performed based on differences versus averages of MUT RET and mutant RBC values in order 





3.1. Assay Optimization 
3.1.1 Reticulocyte Enrichment for MN-RET Analysis 
 Proof-of-concept work aimed at enriching RET for the micronucleus assay was 
accomplished with mouse blood. Using gamma-irradiation to generate a range of MN-RET 
frequencies, we compared flow cytometry-based %MN-RET frequencies that were generated 
with and without immunomagnetic enrichment of CD71+ RET. Whereas standard processing of 
blood samples exhibited a mean %RET value of 1 ± 0.55%, those that were enriched for CD71+ 
cells averaged 67 ± 29%, a 68-fold increase. Even so, Figure 1 shows MN-RET frequencies for 
samples split between the standard flow cytometric analysis and those enriched for CD71+ RET 
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values of 0.97 and 0.96, respectively. Bland-Altman analysis revealed little bias (0.09% MN-
RET), with relatively narrow upper and lower levels of agreement.  
 Success with mouse blood encouraged us to develop an analogous RET-enrichment 
method for the human blood micronucleus assay. The most satisfactory results were obtained 
with the MACS® cell separation platform. Whereas the majority of human blood samples 
exhibited CD71+ RET frequencies in the range 0.1 to 0.3% prior to separation, post-
immunomagnetic column samples averaged 26%—on the order of 100-times more 
concentrated. Figure 2 shows %MN-RET data from column-enriched samples for 14 different 
volunteers (5 males, 9 females). Each blood sample was split into 3-4 technical replicates. 
Since several volunteers provided multiple blood samples over a 5-week period, it was possible 
to evaluate inter- as well as intra-subject MN-RET variation. Based on REML analysis, the vast 
majority of variability is attributable to inter-subject differences (77.3%), with much less 
variability due to technical replicate (17.3%) or intra-subject variation (5.4%). (Note that for 
Figure 2 and others that display log transformed data, the visual impact of the between 
individual variability is reduced.) 
  
3.1.2 Blood Storage for PIG-A Analysis 
 The blood freezing and thawing method that has been proven effective for rodent 
samples was evaluated for its compatibility with human blood-based PIG-A analyses. Results 
for eight subjects are provided in Figure 3, and shows mutation frequency data under three 
blood storage conditions: i) analyzed within 24 hr, ii) refrigerated for up to 5 days, and iii) 
frozen/thawed. REML analysis indicated that technical replicates and storage condition 
contributed low levels of variability to MUT RET frequencies—18.5 and 0%, respectively. The 
majority of the observed variability (81.5%) was attributable to inter-subject differences. 
 Figure 4 shows MUT RET data from the same 14 volunteers that were analyzed for 
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storage and subsequent processing for MUT RET frequency determinations. Since several 
volunteers provided multiple blood samples over a 5-week period, it was possible to evaluate 
inter- as well as intra-subject MUT RET variation. Based on REML analysis, the vast majority of 
variability is attributable to inter-subject differences (90.9%). Again, considerably less variability 
was explained by technical replicate (9.1%) or intra-subject variation (0%). 
   
3.2 Investigating Sources of Inter-Subject Variation 
3.2.1 MN-RET: Age and Sex Effects 
 Using the optimized MN-RET assay, we investigated the effects of age and sex. Figure 5 
shows MN-RET frequencies for 338 individuals as a function of age, with sexes indicated by 
different symbols. The values ranged from 0.01 to 0.79%, and the overall mean and standard 
deviation was 0.146 ± 0.10%.  
 Visually, no age- or sex-effect is apparent. This qualitative impression is supported by 
several analyses. First, means and standard deviations for %MN-RET are very similar for males 
and females—0.15 ± 0.10% and 0.14 ± 0.10%, respectively. Second, when subjects are 
categorized by age (< 1, 1-10, 11-20, 21-30 yr, etc.), two-way ANOVA results indicate that 
neither age group, sex, or an age group x sex interaction effect reaches statistical significance 
(p = 0.14, 0.34, and 0.53, respectively). Finally, when age is treated as a continuous variable, 
the mean fit line is found to describe the data as well as a best fit line (p = 0.49).   
 
3.2.2 MUT RET: Age and Sex Effects 
 Using the optimized PIG-A assay, we investigated the effects of age and sex on MUT 
RET frequency. Figure 6 shows MUT RET frequencies for 344 individuals as a function of age, 
with sexes indicated by different symbols. The values ranged from 0 to 1109 MUT RET x 10-6, 
and the overall mean and standard deviation was 8.9 ± 62 x 10-6. When two extreme outliers are 
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deviation was 4.7 ± 5.0 x 10-6. 
 Visually, Figure 6 (left panel) suggests age and sex may influence MUT RET 
frequencies. These qualitative impressions are supported by several quantitative analyses. 
First, excluding two extreme (high) outliers, the mean MUT RET frequency is modestly elevated 
in males—5.9 ± 6.2 compared to 3.5 ± 3.3 per million for females. Second, when subjects are 
categorized by age group (< 1, 10-11, 11-20, 21-30 yr, etc.), two-way ANOVA results indicate 
that age group and sex reach statistical significance (p < 0.001 for both; whereas age group x 
sex interaction p = 0.01). Finally, when age is treated as a continuous variable, polynomial 
(cubic) fits describe the data significantly better than mean fit lines (p < 0.001 in the case of 
females and males; see Figure 6 middle and right panels).  
 Having identified age as a significant factor, we used the decade of age categorization to 
evaluate responsible group(s). A graphical representation of pair-wise test results is shown in 
Figures 7 and 8—females and males, respectively. The age group < 1 yr was found to exhibit 
significantly lower MUT RET values than every other age group except for 1-10 (low N), and this 
was evident irrespective of sex. In the case of males, one other significant difference was 
evident between the age groups 21-30 and 51-60, with higher values observed with increased 
age. Note that while males 61+ actually exhibited the highest mean MUT RET value, the 
number of subjects in this group was low compared to each of the other groups. 
 
3.3 Relationship Between Biomarkers 
 Figure 9 shows each subjects‘ MN-RET value graphed against their corresponding MUT 
RET value. There is a striking lack of correlation between these two biomarkers. Indeed, the 
meant fit line explains the relationship between the two biomarkers as well as a best fit line (p = 
0.82).  
 PIG-A assay results have focused on the youngest fraction of circulating erythrocytes, 
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mutant phenotype erythrocytes exhibit a shortened lifespan [Ware et al., 1995]. Data generated 
over the course of the current experiments supports this view. Figure 10 (left panel) shows each 
subject‘s MUT RET frequency graphed against the corresponding mutant RBC frequency. While 
the values are clearly correlated, the resulting slope (1.23) indicates that mutant RBC are 
considerably lower than MUT RET. This is reinforced by the Bland-Altman analysis (Figure 10, 
right panel). Beyond showing a negative bias, the dispersion structure indicates the bias is not 




4.1 Major Findings 
 The results presented herein support the effectiveness and reliability of the new 
processing methods that include enrichment of CD71+ RET for subsequent MN-RET scoring, 
and storage of blood samples for deferred PIG-A assay analysis. These updated methods 
overcome technical issues that would have otherwise represented challenging obstacles to 
many, if not most, human biomonitoring applications. 
 Using the improved methodology, we found the variability of MN-RET and MUT RET 
measurements to be dominated by inter-subject variation, with only a minor contribution from 
intra-subject variability—at least over a 5-week period. Our analysis of hundreds of relatively 
healthy individuals over a wide range of ages suggest that neither age or sex significantly 
influence MN-RET frequency over the age range studied, 0 - 73 yr. On the other hand, MUT 
RET values were affected by age and sex, with the lowest frequencies being observed in the 
youngest subjects, and with males exhibiting moderately higher frequencies than females. It is 
important to acknowledge that, while these factors attained high statistical significance, some of 
the absolute differences were relatively modest. For instance, the overall mean MUT RET 
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appeared to be more substantial. For instance, in the case of the age groups < 1 and 60+ yr, 




 The results presented herein have important implications for designing human 
biomonitoring studies using these genotoxicity biomarkers. 
i. Given the effect that age and sex have on MUT RET frequencies, it will be important to 
balance experimental groups with these factors in mind. This design element would 
appear to be less critical in the case of the MN-RET endpoint. 
 
ii. We found that for both the MN-RET and MUT RET biomarkers, the majority of the 
variability is attributable to inter-subject differences, with little effect of blood collection 
time (i.e., intra-subject variability). Consequently, relatively large numbers of volunteers 
will be necessary to adequately power human biomonitoring studies when comparisons 
are restricted to differences among subjects. On the other hand, lower numbers of 
volunteers will be necessary for experimental designs that are compatible with the 
collection of pre-intervention blood samples. In these cases, subject-specific baseline 
MN-RET and/or PIG-A mutation values will be available for consideration, an 
experimental design that will significantly reduce the number of study participants 
necessary to achieve a given level of statistical power. 
 
iii. There was a marked absence of correlation between individuals‘ MN-RET and MUT 
RET frequencies. For several reasons, this was an anticipated result. First, these 
biomarkers reflect distinct types of genomic damage—chromosomal damage versus 
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exhibited markedly dissimilar MN-RET and MUT RET responses [Dertinger et al., 2012; 
Bhalli et al., 2013; Guérard et al., 2013; Elhajouji et al., 2018]. Third, MacGregor and 
colleagues [1997] reported a similar lack of correlation among several diverse human 
blood genotoxicity endpoints. With this information, investigators that are interested in 
adding a genotoxicity component to their human biomonitoring studies are advised to 
conduct multiple, complementary assays. The cost of performing multiple assays is 
incremental and modest compared to the costs associated with subject recruitment and 
other considerations, and the value added has the potential of being dramatic. This 
added value is readily accomplished by combining the MN-RET and PIG-A assays given 
their low blood volume requirements and the complementary nature of the genomic 
damage detected. 
 
iv. MUT RET and MUT RBC frequencies are correlated, and as expected, MUT RBC 
values consistently underestimate MUT RET frequencies. While systematic 
underestimation may not always be problematic, we are more concerned that Bland-
Altman analysis shows a skewed dispersion structure whereby MUT RBC more greatly 
underestimate MUT RET as mutant cell frequencies increase. It is a fact that MUT RET 
analysis requires more resources relative to MUT RBC analysis—the former requires 
immunomagnetic separation, the latter does not. Even so, the MUT RET endpoint is 
demonstrably the preferred population of erythrocytes to study in the case of human 
blood biomonitoring studies.  
  
4.2 Future Studies 
 Even in the case of MUT RET, where age and sex were found to be significant factors, 
the majority of the variability remains unexplained. Future work is needed to identify host and 
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RET frequencies. That information would contribute to the design of more efficient human blood 
genotoxicity biomonitoring studies and would add fundamental knowledge to the field of cancer 
research, which considers genomic damage a key factor in the multistep process of 
carcinogenesis [Hanahan and Weinberg, 2000, 2011]. 
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Figure Legends  
Figure 1. Micronucleated reticulocyte (MN-RET) frequencies are graphed for mouse blood 
samples that were each processed in two manners: immunomagnetically enriched versus not 
enriched for CD71-positive reticulocytes prior to flow cytometric analysis. The left panel shows 
linear regression and correlation analyses that provide metrics of accuracy (m = 0.96) and 
precision (r2 = 0.97). The right panel shows the difference in MN-RET frequency for each 
sample in relation to the average value. Bias (solid black line) and upper and lower limits of 
agreement (dashed lines) were derived from Bland-Altman analysis.     
 
Figure 2. Log10 transformed micronucleated reticulocyte (MN-RET) frequencies are graphed 
for fourteen volunteers, 5 of which provided blood over a 5-week period. Blood samples were 
processed as 3-4 technical replicates, and these individual MN-RET measurements are shown. 
Results from this nested design were evaluated by Restricted Maximum Likelihood analysis and 
demonstrated that inter-subject, intra-subject (collection time), and technical replicate factors 
contributed 77.3, 5.4, and 17.3% of the observed variation, respectively.  
 
Figure 3. Log10 transformed mutant reticulocyte (MUT RET) frequencies are graphed for eight 
volunteers. Each blood sample was processed after being stored under 3 conditions: 
refrigerated ≤ 24 hr, refrigerated ≤ 5 days, and stored frozen until day of analysis. Blood 
samples were processed as 4 technical replicates, and these individual MUT RET 
measurements are graphed. Results from this nested design were evaluated by Restricted 
Maximum Likelihood analysis and showed that inter-subject, storage condition, and technical 
replicate factors contributed 81.5, 0, and 18.5% of the observed variation, respectively.  
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fourteen volunteers, 6 of which provided blood over a 5-week period. Blood samples were 
processed as 3-4 technical replicates, and these individual mutant measurements are shown. 
Results from this nested design were evaluated by Restricted Maximum Likelihood analysis and 
demonstrated that inter-subject, intra-subject (collection time), and technical replicate factors 
contributed 90.9, 0, and 9.1% of the observed variation, respectively.  
 
Figure 5. Log10 transformed micronucleated reticulocyte (MN-RET) frequencies are graphed 
versus age (yr), with males as blue squares and females as red triangles. An ANOVA platform 
indicates that the best linear fit line (green solid line) does not describe the data any better than 
the mean fit line (orange), p = 0.49. The dashed lines correspond to the 95% prediction interval. 
 
Figure 6. Log10 transformed mutant reticulocyte (MUT RET) frequencies are graphed versus 
age (yr), with males as blue squares and females as red triangles. ANOVA indicates that cubic 
polynomial fits (orange solid lines) describe the data better than mean fit lines (green lines), p < 
0.001 for both females (center panel) and males (right panel). The dashed lines correspond to 
95% prediction intervals. 
 
Figure 7. Female volunteers‘ log10 transformed mutant reticulocyte (MUT RET) frequencies are 
graphed according to age group. Each group mean is indicated by a green line. Circles‘ 
diameters represent 95% confidence intervals. Tukey-Kramer test results indicate the age group 
< 1 yr exhibited significantly lower MUT RET values compared to every other age group except 
for 1-10 yr (although it should be noted that group has low N).  
 
Figure 8. Male volunteers‘ log10 transformed mutant reticulocyte (MUT RET) frequencies are 
graphed according to age group. Each group mean is indicated by a green line. Circles‘ 
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< 1 yr exhibited significantly lower MUT RET values compared to every other age group except 
for 1-10 yr (although it should be noted that group has low N). One additional significant 
difference was identified, between age groups 21-30 and 51-60. Note that while males 61+ 
actually exhibited the highest mean MUT RET value, the number of subjects in this group was 
low compared to each of the other groups. 
 
Figure 9. Each subject‘s log10 transformed micronucleated reticulocyte (MN-RET) frequency is 
graphed against their corresponding mutant reticulocyte frequency, with males as blue squares 
and females as red triangles. ANOVA indicates that the best linear fit line (green) does not 
describe the data any better than the mean fit line (red), p = 0.82. 
 
Figure 10. The left panel shows each subjects‘ mutant reticulocyte (MUT RET) frequency 
graphed against their corresponding mutant erythrocyte (MUT RBC) frequency. The values are 
correlated (r2 = 0.71), but show a bias for lower MUT RBC values (m = 1.23).  The right panel 
shows the difference in MUT RET and MUT RBC frequency for each sample in relation to the 
average value. Bias (solid black line) and upper and lower limits of agreement (dashed lines) 
were derived from Bland-Altman analysis. A linear regression line has been added to highlight 
the fact that there is a skewed dispersion structure to the data whereby MUT RBC more greatly 
underestimate MUT RET as mutant cell frequencies increase.       
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Table I. Subject Information. 
Source Total No. Subjects 
(Males/Females) 






300 (150/150) 19 - 73 38.2 ± 12.1 Self-reported healthy 
adults 
URMC, Dept. Radiation 
Oncology 





26 (10/16) 0 (cord blood) - 1.2 0.2 ± 0.3 Healthy (cord bloods) or 
infants with congenital 
heart defect 
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